Clinical trial · Interventional

A Study of ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma

Phase II Evaluation of Oral ALRT1057 in Patients With AIDS-Related Kaposi's Sarcoma.

NCT00002188CI-TRIAL-00000002completedPhase 2ClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

The purpose of this study is to see if ALRT1057 is safe and effective in treating patients with AIDS-related Kaposi's sarcoma (KS).

Conditions

Conditions (2)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
HIV Infections	—	UNRESOLVED	—
Sarcoma, Kaposi	Kaposi Sarcoma	ONTOLOGY_EXACT	0.98

Interventions

Interventions (1)

Intervention	Type	Mapped drug	Match
Alitretinoin	Drug	Alitretinoin	ALIAS

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years

Show eligibility criteria text

Inclusion Criteria

Patients must have:

* HIV positive status and histologic confirmation of KS.
* CD4 count \> 200 mm3 (required of one-half of patients).
* Minimum of 6 mucocutaneous KS lesions, including at least 3 raised lesions meeting criteria for "indicator" lesions.
* Acceptable organ system function.

Exclusion Criteria

Co-existing Condition:

Patients with the following conditions or symptoms are excluded:

Serious or intercurrent illness or infection that would interfere with the ability of the patient to carry out the treatment program.

Prior Medication:

Excluded:

* Systemic therapy for KS within 30 days.
* Local or topical therapy for KS indicative lesions within 60 days.
* Systemic therapy with vitamin A in doses exceeding 15,000 IU per day or other retinoid class drug.

Required:

Approved antiretroviral therapy.

References

Publications (0)

Data not yet available

No reference posted for this study.